155 related articles for article (PubMed ID: 16123473)
1. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes.
Danne T; Becker RH; Heise T; Bittner C; Frick AD; Rave K
Diabetes Care; 2005 Sep; 28(9):2100-5. PubMed ID: 16123473
[TBL] [Abstract][Full Text] [Related]
2. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes.
Rave K; Klein O; Frick AD; Becker RH
Diabetes Care; 2006 Aug; 29(8):1812-7. PubMed ID: 16873785
[TBL] [Abstract][Full Text] [Related]
3. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.
Pettis RJ; Hirsch L; Kapitza C; Nosek L; Hövelmann U; Kurth HJ; Sutter DE; Harvey NG; Heinemann L
Diabetes Technol Ther; 2011 Apr; 13(4):443-50. PubMed ID: 21355716
[TBL] [Abstract][Full Text] [Related]
4. Insulin glulisine.
Robinson DM; Wellington K
Drugs; 2006; 66(6):861-9. PubMed ID: 16706558
[TBL] [Abstract][Full Text] [Related]
5. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.
Ulrich H; Snyder B; Garg SK
Vasc Health Risk Manag; 2007; 3(3):245-54. PubMed ID: 17703632
[TBL] [Abstract][Full Text] [Related]
6. Insulin glulisine: a review of its use in the management of diabetes mellitus.
Garnock-Jones KP; Plosker GL
Drugs; 2009 May; 69(8):1035-57. PubMed ID: 19496630
[TBL] [Abstract][Full Text] [Related]
7. Insulin glulisine.
Cox SL
Drugs Today (Barc); 2005 Jul; 41(7):433-40. PubMed ID: 16193096
[TBL] [Abstract][Full Text] [Related]
8. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study.
Horvath K; Bock G; Regittnig W; Bodenlenz M; Wutte A; Plank J; Magnes C; Sinner F; Fürst-Recktenwald S; Theobald K; Pieber TR
Diabetes Obes Metab; 2008 Jun; 10(6):484-91. PubMed ID: 17764465
[TBL] [Abstract][Full Text] [Related]
9. Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes.
Rayman G; Profozic V; Middle M
Diabetes Res Clin Pract; 2007 May; 76(2):304-12. PubMed ID: 17113676
[TBL] [Abstract][Full Text] [Related]
10. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes.
Garg SK; Ellis SL; Ulrich H
Expert Opin Pharmacother; 2005 Apr; 6(4):643-51. PubMed ID: 15934890
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine.
Becker RH; Frick AD
Clin Pharmacokinet; 2008; 47(1):7-20. PubMed ID: 18076215
[TBL] [Abstract][Full Text] [Related]
12. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.
Danne T; Lüpke K; Walte K; Von Schuetz W; Gall MA
Diabetes Care; 2003 Nov; 26(11):3087-92. PubMed ID: 14578244
[TBL] [Abstract][Full Text] [Related]
13. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique.
Becker RH; Frick AD; Burger F; Scholtz H; Potgieter JH
Exp Clin Endocrinol Diabetes; 2005 May; 113(5):292-7. PubMed ID: 15926116
[TBL] [Abstract][Full Text] [Related]
15. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
[TBL] [Abstract][Full Text] [Related]
16. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
[TBL] [Abstract][Full Text] [Related]
17. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine.
Garg SK; Rosenstock J; Ways K
Endocr Pract; 2005; 11(1):11-7. PubMed ID: 16033730
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
[TBL] [Abstract][Full Text] [Related]
19. Insulin glulisine: a faster onset of action compared with insulin lispro.
Heise T; Nosek L; Spitzer H; Heinemann L; Niemöller E; Frick AD; Becker RH
Diabetes Obes Metab; 2007 Sep; 9(5):746-53. PubMed ID: 17593235
[TBL] [Abstract][Full Text] [Related]
20. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
